Adjuvant composition for a vaccine
An adjuvant composition for a vaccine includes one or more substantially isoparaffinic hydrocarbon oils having C17 and/or C18 isoparaffins, and one or more surfactants. A vaccine includes the adjuvant composition.
1 . An adjuvant composition for a vaccine comprising, relative to the total weight of the adjuvant composition:
at least 40% by weight of hydrocarbon oil comprising a content by weight of isoparaffins ranging from 90 to 100% relative to the total weight of the hydrocarbon oil, said isoparaffins including:
isoparaffins having 16 carbon atoms, isoparaffins having 17 carbon atoms, and isoparaffins having 18 carbon atoms, in a combined amount ranging from 80 to 98% by weight, relative to the total weight of the hydrocarbon oil; or
isoparaffins having 17 carbon atoms and isoparaffins having 18 carbon atoms, in a combined amount ranging from 80 to 98% by weight, relative to the total weight of the hydrocarbon oil;
and
from 1 to 15% by weight of one or more surfactant(s).
2 . The composition according to claim 1 , wherein said isoparaffins comprise, relative to the total weight of isoparaffins, at least 2% by weight of isoparaffins having 17 carbon atoms and/or isoparaffins having 18 carbon atoms.
3 . The composition according to claim 1 , wherein the surfactant is selected from among non-ionic surfactants.
4 . The composition according to claim 1 , wherein the surfactant is a sorbitan fatty acid ester.
5 . The composition according to claim 1 , comprising, relative to the total weight of the composition:
from 60 to 98% by weight of hydrocarbon oil comprising a content by weight of isoparaffins ranging from 95 to 100% relative to the total weight of the hydrocarbon oil, said isoparaffins including isoparaffins having 17 carbon atoms or 18 carbon atoms; and
from 2 to 10% by weight of one or more surfactant(s).
6 . The composition according to claim 1 , further comprising an oil other than said hydrocarbon oil.
7 . A vaccine comprising the adjuvant composition as defined in claim 1 and at least one antigen.
8 . The vaccine according to claim 7 , wherein the vaccine is in the form of a water-in-oil emulsion.
9 . The vaccine according to claim 8 , wherein the mass ratio between the aqueous phase and the fatty phase of the water-in-oil emulsion ranges from 50/50 to 10/90.
10 . The composition according to claim 1 , wherein the surfactant is selected from among sorbitan esters.
11 . The composition according to claim 1 , wherein the surfactant is a sorbitan monooleate.
12 . The composition according to claim 6 , wherein the oil other than said hydrocarbon oil is selected from among n-paraffins.
13 . The composition according to claim 12 , wherein the n-paraffins comprise from 14 to 30 carbon atoms.
14 . The composition according to claim 12 , exhibiting a mass ratio of hydrocarbon oil/n-paraffin that ranges from 60/40 to 99/1.
15 . The vaccine according to claim 8 , wherein the mass ratio between the aqueous phase and the fatty phase of the water-in-oil emulsion ranges from 40/60 to 20/80.